REWIEV ARTICLE / ПРЕГЛЕД ЛИТЕРАТУРЕ

The impact of currently used oral antihyperglycemic drugs on dysfunctional adipose tissue

Dragana Tomić-Naglić[1,2], Milena Mitrović[1,2], Jovanka Novaković-Paro[1,2], Radoslav Pejin[1,2], Đorđe S. Popović[1,2], Slađana Pejaković[1], Biljana Srdić-Galić[2], Damir Benc[1,2]

[1]Clinical Center of Vojvodina, Clinic for Endocrinology, Diabetes and Metabolic Disorders, Novi Sad, Serbia;
[2]University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia

SUMMARY
Obesity is a disease with pandemic frequency, often accompanied by chronic metabolic and organic complications. Type 2 diabetes mellitus (T2DM) is among the most common metabolic complications of obesity. The first step in the treatment of T2DM is medical nutrition therapy combined with moderate physical activity and with advice to patients to reduce their body weight. Pharmacotherapy starts with metformin, and in the case of inadequate therapeutic response, another antihyperglycemic agent should be added. The most clinical experience exists with sulfonylurea agents, but their use is limited due to high incidence of hypoglycemia and increase in body weight. Based on the fact that dysfunction of adipose tissue can lead to the development of chronic degenerative complications, precise use of drugs with a favorable effect on the functionality of adipose tissue represents an imperative of modern T2DM treatment. Antihyperglycemic drugs of choice in obese individuals are those which cause maturation of adipocytes, improvement of secretion of protective adipokines, and redistribution of fat mass from visceral to subcutaneous depots. Oral antihyperglycemic agents that can affect the functionality of adipose tissue are metformin, SGLT-2 inhibitors, DPP-4 inhibitors, and thiazolidinediones.
Keywords: adipose tissue; adipokines; type 2 diabetes mellitus; treatment

INTRODUCTION

Obesity is a disease characterized by the excessive accumulation and storage of adipose tissue in the body, which presents a risk to health and can lead to many complications [1, 2, 3]. Adipose tissue is a metabolically active organ with both endocrine and paraendocrine effects [3]. Dysfunction of this tissue is clearly associated with more frequent occurrence of visceral obesity, type 2 diabetes mellitus (T2DM), insulin resistance (IR), and chronic subclinical inflammation [3, 4, 5]. Namely, fat tissue makes up approximately 10–20% of the total body mass, while that percentage in obese persons can be four to five times greater [6, 7]. Reduction in adenosine monophosphate-activated protein kinase α (AMPKα), peroxisome proliferator-activated receptor gamma, coactivator 1 α (PPARGC1A, PGCα), and peroxisome proliferator-activated receptor α (PPARα) genes' expression decreases the oxidative capacity of adipocytes, and thereby inhibits the possibility of energetic metabolism turnover in the adipose tissue, which represents the main pathophysiological model that causes obesity [8]. Knowing this fact, current therapy of T2DM and the development of modern antihyperglycemic drugs are based on the stimulation of those impaired pathways in the adipose tissue.

It is known that in the presence of excessive obesity the possibility of prediabetes development increases, which can, in the later course, lead to the onset of T2DM, which imposes the need for implementation of the active screening procedures among populations with a great propensity to develop diabetes, like among obese individuals, but also a need to intensify their treatment [9]. Populations with greater susceptibility for T2DM development include subjects with prediabetes, obese and overweight individuals, subjects with established cardiovascular diseases, and persons older than 45 years [9]. In these cases, it is indicated to perform the two-hour oral glucose tolerance test with 75 g of glucose [9, 10].

The consequence of dysfunctional adipose tissue is sustained lipid toxicity, followed by IR and associated metabolic complications. These metabolic alterations negatively affect global metabolic homeostasis. The adipose tissue distribution optimization and its functional metabolic flexibility are promoting insulin sensitivity and metabolic control in patients with T2DM. These therapeutic approaches require a deep understanding of adipose tissue in all broad aspects. In this article, we will discuss the influence of the different glucose-lowering agents on adipose tissue depots with respect to adipokines' production, plasticity, cellular composition, as well as metabolic signatures of pharmacotherapy of T2DM [9, 10].

Randomized controlled studies showed that in persons with the higher risk of developing T2DM, lifestyle changes and/or drug therapy can prevent progression of the disease [11]. Considering that at the moment of diabetes

Correspondence to:
Dragana TOMIĆ-NAGLIĆ
Hajduk Veljkova 1
21000 Novi Sad, Serbia
dragana.tomic-naglic@mf.uns.ac.rs

diagnosis 80–90% of patients are overweight or obese, the American Diabetes Association guidelines recommend the introduction of antihyperglycemic drugs with weight-reducing or at least weight-neutral properties in patients with body mass index (BMI) ≥ 27 kg/m², whenever other circumstances allow it [10]. Antihyperglycemic drugs that stimulate weight reduction are metformin, α-glycosidase inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonist, amylin mimetics, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Dipeptidyl peptidase-4 inhibitor (DPP-4) inhibitors are weight-neutral to weight-reducing, while secretagogues, thiazolidinediones, and insulin are related to a significant increase in body weight [9, 10].

Therapy

Initial therapy for T2DM surely includes lifestyle changes such as intensification of physical activity to minimum of 150 min./week and changes in dietary habits [9, 10, 11].

Metformin is the first line of drug therapy, according to current recommendations [9, 10]. If this treatment fails to give expected results in a period of three months, combination therapy should be introduced [9, 10]. While choosing the right additional antihyperglycemic drug, it is necessary to bear in mind its effect on the body weight [9, 10, 12].

The list of available glucose-lowering agents is shown in Table 1.

Sulfonylureas are drugs that have been used for several decades. They show high efficiency in HbA1c reduction, and the evidence from earlier landmark studies indicates their positive effect on the delay of chronic microvascular complication development. However, nowadays, at least in developed countries, they are replaced with other drugs, because they cause high rates of hypoglycemia, tend to increase body weight, and have a negative effect on spontaneous vasodilatation of coronary arteries [12].

α-Glucosidase inhibitors have limited use, considering their modest efficiency in HbA1c reduction accompanied

Table 1. Properties of available glucose-lowering agents that may tailor the individualized treatment choice in patients with T2DM

Class	Compound(s)	Cellular mechanism(s)	Primary physiological action(s)
Biguanides	Metformin	activates AMP-kinase	↓ hepatic glucose production
Sulfonylureas	2nd generation: Glyburide Glipizide Gliclazide Glimepiride	closes KATP channels on β-cell plasma membranes	↑ insulin secretion
Meglitinides	Repaglinide Nateglinide	closes KATP channels on β-cell plasma membranes	↑ insulin secretion
Thiazolidinediones	Pioglitazone Rosiglitazone	activates the nuclear transcription factor PPARγ	↑ insulin sensitivity
α-Glucosidase inhibitors	Acarbose Miglitol	inhibits intestinal α-glucosidase	slows intestinal carbohydrate digestion/absorption
DPP-4 inhibitors	Sitagliptin Vildagliptin Saxagliptin Linagliptin Alogliptin	inhibits DPP-4 activity, increasing postprandial active incretin (GLP-1) concentrations	↑ insulin secretion ↓ secretion of glucagon
Bile acid sequestrants	Colesevelam	binds bile acids in intestinal tract, increasing hepatic bile acid production	?↓ hepatic glucose production ?↑ incretin levels
Dopamine-2 agonists	Bromocriptine	activates dopaminergic receptors	modulates hypothalamic regulation of metabolism ↑ insulin sensitivity
SGLT-2 inhibitors	Canagliflozin Dapagliflozin Empagliflozin	inhibits SGLT-2 receptors in the proximal nephron	blocks glucose reabsorption by the kidney, increasing glucosuria
GLP-1 receptor agonists	Exenatide Liraglutide Albiglutide Lixisenatide Dulaglutide	activates GLP-1 receptors	↑ insulin secretion ↓ glucagon secretion slows gastric emptying ↑ satiety
Amylin mimetics	Pramlintide	activates amylin receptors	↓ glucagon secretion slows gastric emptying ↑ satiety
Insulins	Lispro Aspart Glulisine Human regular Human NPH Glargine Detemir Degludec	activates insulin receptors	↑ glucose disposal ↓ hepatic glucose production

AMP-kinase – adenosine monophosphate-kinase; KATP channels – adenosine triphosphate-sensitive potassium channels;
PPARγ – peroxisome proliferator-activated receptor gamma; DPP-4 – dipeptidyl peptidase-4; GLP-1 – glucagon-like peptide-1;
SGLT-2 – sodium-glucose cotransporter-2; NPH – neutral protamine Hagedorn

by gastrointestinal side effects (diarrhea, flatulence) [12]. However these drugs found their place in the treatment of obese patients after the bariatric surgery. A number of patients treated with bariatric surgery procedures report the so-called "dumping syndrome," and the use of acarbose showed a decrease in incidence of this complication, thus leading to an improvement in the quality of life in these patients [13].

Bile acid sequestrants are used mainly in treating hyper-cholesterolemia, since their main effect is low-density li-poprotein (LDL) cholesterol lowering [14]. However, they demonstrate satisfying glucose-lowering effect (HbA1c reduction in the 0.3–1.1% range is reported), in particular colesevelam [14]. Their physiological actions remain unknown, with the assumption that they are based on the incretin effect through the stimulation of incretin secre-tion (GLP-1 and others) and on the impact on the hepatic glucose production [14].

Bromocriptine is one of the newer antihyperglycemic agents, with a unique central mechanism of action. Nor-mal weight individuals have maximum prolactin secretion during the night, because of the low dopaminergic activity, while after waking up prolactin level decreases [15]. Obese individuals with IR have prolactin levels two times higher during the day compared to healthy persons [15]. The main mechanism of the bromocriptine antihyperglycemic action is an increase in the daily dopaminergic activity and lower-ing of the prolactin level [15]. Previous experiences show that bromocriptine monotherapy or its combination with other oral antihyperglycemic agents leads to the reduction of HbA1c ranging from 0.4% to 0.7% [15]. Even though it shows low/mild HbA1c reduction effect, benefits of bro-mocriptine use are weight reduction combined with low incidence of hypoglycemia [12, 15]. The side effects of bro-mocriptine (orthostatic hypotension, nausea, vertigo, and possible interactions with other plasma protein-binding drugs) limit its use [12, 15]. Since postprandial glycemia is an equally important indicator of glycoregulation and of HbA1c and fasting glycemia, large efforts have been made recently in the therapeutic targeting of this particular as-pect of diabetes management. Efficiency in reduction of postprandial glycemia are shown by meglitinides, GLP-1 receptor agonists (mainly short-acting ones), DPP-4 inhibi-tors, SGLT-2 inhibitors, and amylin mimetics [16].

ORAL ANTIHYPERGLYCEMIC AGENTS AND DYSFUNCTIONAL ADIPOSE TISSUE

Metformin

Metformin has been used in the treatment of T2DM since the 1950s. It is already known that metformin reduces body weight [9, 10]. However, the greatest reduction of fat mass has actually been detected in subcutaneous abdomi-nal depots [17]. Also, it is shown that metformin causes the highest insulin stimulated glucose uptake in the viscer-al adipose tissue [17]. Fujita et al. [17] have questioned the positive effect of this drug on dysfunctional adipose tis-

sue, showing that in an in vitro model metformin actually blocks the differentiation of visceral tissue preadipocytes into mature adipocytes and that it does not reduce the size or the number of adipocytes, which could be expected as the positive effect [17]. This way, the maturation of preadi-pocytes and the secretion of adipocyte final maturation in-dicators, such as adiponectin, which demonstrates a strong anti-inflammatory and antidiabetic effect, are suppressed [17]. On the other hand, positive effects of metformin are shown among women with polycystic ovary syndrome. Tan et al. [18] published that metformin use significantly lowers the level of chemerine, an adipocytokine involved in the pathogenesis of IR and hypertriglyceridemia [18]. Metformin's main mechanism of action in adipose tissue is the activation of adenosine monophosphate (AMP)-kinase and lipogenesis suppression in preadipocytes, and the greatest antihyperglycemic effect is achieved through lowering the hepatic glucose production [19].

DPP-4 inhibitors

DPP-4 inhibitors are among newer antihyperglycemic agents, and according to the current diabetes guidelines are referred to as weight-neutral [9, 10]. DPP-4 are prote-ases located on the cell surface, but there is also a soluble fraction of this proteases in plasma [20]. Recently, this en-zyme was recognized as an adipocytokine, responsible for the development of the metabolic syndrome and T2DM [20]. DPP-4 interfere with insulin signalization through paracrine and endocrine ways [20].

Although until now they were referred to as weight-neu-tral, recent studies on a DPP-4 inhibitor, evogliptin, in an animal model, indicate possible beneficial effects in term of body weight reduction. Namely, this drug shows the possi-bility of changing energy balance within the white adipose tissue [21]. Evogliptin in an animal model does not increase thermogenesis in white adipose tissue, but, contrary, reduces uncoupling protein-1(UCP-1) level in mitochondria of adi-pocytes [21]. It is shown in an animal model that evogliptin induces energy consumption with the help of increased expression of cytochrome c oxidase subunit 4 isoform 1(Cox4I1), which correlates with an increased concentra-tion of protein molecule PPARGC1A [21]. This protein is directly involved in the transcription processes that stimulate production of enzymes necessary for mitochondrial biogen-esis and energy consumption [21]. Also, PPARGC1A stimu-lates the differentiation of muscle fibers, and has protective effect in terms of obesity development [20, 21]. Evogliptin use led to a decrease in leptin level, which can be a result of weight reduction or a possible consequence of a decrease in the level of leptin resistance [21]. The effect of decreasing leptin resistance is just a hypothetical one, since authors did not measure the expression of leptin receptor [21]. Similar effect in humans is caused by vildagliptin [21].

SGLT-2 inhibitors

In the last 10 years, a new therapeutic approach has been developed, which does not include the use of insulin in

the treatment of T2DM. Under physiological conditions, glucose that is excreted in primary urine is entirely reabsorbed back to plasma in renal tubules, so less than 1% of glucose is excreted by urine [21]. Under SGLT-2 receptor inhibition conditions, a major part of excreted glucose does not go through the reabsorption process – it stays in the urine and is eliminated from the body in this way [21].

Until now there have been some concerns over the fact that the use of SGLT-2 inhibitors increases the LDL-cholesterol levels. However, this group of agents demonstrates a positive effect on the lipid profile through decreasing the levels of triglycerides and increasing the levels of C2 sub-fraction of high-density lipoprotein cholesterol, thus reducing the overall atherogenic risk. One of the explanations for their antiatherogenic effect lays in the fact that SGLT-2 inhibitors suppress the transformation of large LDL particles into small dense LDL particles, which carry great atherogenic potential but are difficult to detect in everyday routine laboratory diagnostics [22]. Additionally, the use of dapagliflozin reduces the BMI level, hepatic transaminases level, and increases the adiponectin level [22]. Non-alcoholic fatty liver disease (NAFLD) is the most common cause of elevated liver enzymes in obese people. It is known that subjects with high level of small dense LDL particles, NAFLD, and low adiponectin level have additionally increased cardiovascular risk [21, 22]. Considering positive effects of dapagliflozin on all mentioned risk factors and also an impact on decreasing the levels of triglycerides, it is clear why it should be used in people with cardiometabolic complications of dysfunctional adipose tissue. Lundkvist et al. [19] conducted a trial among 50 obese individuals with prediabetes, based on previous favorable experiences in body weight management among obese patients with T2DM. The results showed the possibility of dapagliflozin use in this population, due to significant weight reduction, reduction of systolic blood pressure, and improved glucose tolerance that have been achieved [19].

Out of SGLT-2 inhibitors, empagliflozin emerged as the most significant agent. The results of the recently completed Empagliflozin Removal of Excess of Glucose Outcome (EMPA-REG OUTCOME) study indicate that empagliflozin significantly reduces cardiovascular mortality and hospitalization rate because of heart failure in patients with T2DM [23]. This is due to the antihyperglycemic effect of SGLT-2 inhibitors but also because of their effect on natriuresis, body weight reduction, blood pressure, and lipid profile. Even though protective effect of empagliflozin in diabetic patients is established, the effects of SGLT-2 inhibitors on this specter of cardiovascular risk factors under prediabetes conditions is known only from animal models [23]. A study by Kusaka et al. [24] was conducted on rats with prediabetes, and it clearly showed that after seven weeks of treatment with empagliflozin, weight reduction was gained despite the increased food intake when compared to the control group. Regarding the fact that there was no difference in the amount of fat mass between the study group and the control group, and that the size of subcutaneous fat mass was smaller in the study group, a ques-

tion on the protective role of empagliflozin has imposed itself. This study has demonstrated that there is a significant difference in the size of adipocytes [24]. Empagliflozin use leads to the histological changes in the structure of adipose tissue, in the sense of reducing the diameter of adipocytes, which have more favorable metabolic impact than insufficiently differentiated adipocytes with large diameter [24]. In relation to metabolic parameters, reduction of HbA1c, lowering of postprandial glycemia, and decrease in insulin level were observed [24]. Although it was noted that empagliflozin does not lower the level of total cholesterol and free fatty acids (FFA), it certainly reduces the rate of lipid peroxidation [24]. On the other hand, people with prediabetes have a high risk of developing cardiovascular diseases [1–5]. Taking into account the favorable effect of empagliflozin on preventing hypertrophy and fibrosis of the left ventricle, SGLT-2 inhibitors could also be used in the treatment of individuals with prediabetes [23, 24].

Thiazolidinediones

It has been clearly proven by now that there is a correlation between IR, T2DM, and adipose tissue dysfunction [1, 2, 4, 5]. One of the key genes responsible for function of adipose tissue is PPARγ [25]. Previous studies have shown that PPARγ plays a role in numerous functions of adipose tissue, such as preadipocytes differentiation and secretion of adipocytokines, as well as controlling the level of inflammation and insulin sensitivity within adipose tissue [25]. As mentioned earlier, important markers of dysfunction and inadequate differentiation of adipose tissue are the larger diameter of adipocytes, reduced expression and low level of circulating adiponectin, and reduced expression of PPARGC1A [25, 26]. Thiazolidinediones are PPARγ agonists, and by that they increase glucose uptake in adipocytes, and prevent FFA release and possible subsequent lipotoxicity, which represents one of the key physiopathogenetic mechanisms in T2DM development [27].

In individuals with IR there is a reduction in several key molecules responsible for insulin activity, such as glucose transporter type 4, PPARGC1A, markers of terminal differentiation of adipose tissue, and insulin receptor substrate [27, 28]. The use of pioglitazone leads to an improvement in insulin sensitivity in non-obese subjects with IR, regardless of its impact on the change in levels of circulating FFA and other lipid and lipoprotein parameters [28]. The explanation of this effect of thiazolidinediones lays in their positive activity on adipose tissue remodeling. The use of this agent leads to the replacement of large adipocytes with well-differentiated and more insulin-sensitive adipocytes with smaller diameter [28]. This kind of adipose tissue remodeling has a positive effect on inflammation, which is one of the leading physiopathogenetic mechanisms of IR and T2DM. In fact, there is a clear correlation between the adipocyte size and the level of circulating interleukin-6 (IL-6). The reduction in size of adipocytes reduces the level of IL-6 in the serum [28]. On the other hand, thiazolidinediones stimulate the production of adiponectin [27, 28]. It was noted that the level of

adiponectin in individuals treated by pioglitazone is the result of increased contribution of high-molecular-weight adiponectin fraction (HMW) adiponectin [28]. HMW adiponectin is highly protective regarding atherosclerosis and T2DM development [1, 2, 3]. PPARγ demonstrates high expression in the adipose tissue. Although the role of thiazolidinediones on PPARγ stimulation is well documented, its role in the expression of this nuclear receptor is still debated [28]. The beneficial effect of pioglitazone is reflected through the redistribution of fat mass in the body. The use of pioglitazone increases body weight and fat mass. However, beneficial metabolic effect of pioglitazone is a result of adipose tissue redistribution, reflected through the reduction in visceral adipose tissue amount and the increase in the amount of subcutaneous fat depots [28, 29].

PARENTERAL PHARMACOTHERAPY

Among the currently available parenteral therapies for obese patients with T2DM, two classes also promote weight loss. Pramlintide, a synthetic form of amylin, induces short-term satiety and may be useful in combination with other agents. A recent study pointed out an improvement in glucose tolerance in diabetic patients in dose-dependent manner, as well as a promotion of insulin secretion [30].

On the other hand, GLP-1 receptor agonist-associated effects are visceral fat specific. Liraglutide stimulated white adipose tissue browning and thermogenesis independently of nutrient intake [31]. Exenatide reduced epicardial, subcutaneous, and liver fat in diabetic patients, in a similar way as liraglutide, activating brown adipose tissue and generating clearance of triglycerides and glucose [32]. Treatments of patients with GLP-1 receptor agonists promote weight loss and increase circulating adiponectin levels. Also, expression of adiponectin receptors in visceral adipose tissue is increased by exenatide administration [32]. Chronic low-grade inflammation has been reported as a connection between obesity and T2DM. Studies suggest that treatment of obese patients with GLP-1 receptor agonists decreases circulating cytokines including monocyte chemoattractant protein-1 plasma concentration and inhibits the expression of inflammatory cytokines in 3T3-L1 adipocytes [32].

Most patients with T2DM require insulin and/or insulin-analog therapy. Despite the presence of various insulin and/or insulin-analog regiments, it is very difficult to achieve an optimal glycemic control in obese patients. The risk of severe hypoglycemia and weight gain have a major impact on metabolic control during the insulin therapy. Less weight gain and reduced risk of hypoglycemia are benefits offered by using long-acting insulin analogs [33].

HOW MIGHT TREATMENT OPTIONS LOOK LIKE IN THE FUTURE?

Today, we have a wide range of options, so that treatment could be tailored for each patient, in most cases combining two or more drugs to achieve recommended HbA1c targets [10]. In the future, there will be likely 50 or more available oral or parenteral drugs to choose from, for pharmacotherapy of diabetic patients. Because of that, the choice of therapy will be strongly personalized and based on the patient's genetic profile. We could expect that genetic testing will be used to distinguish different types of adipose tissue, different cytokine receptor expression and to diagnose subtypes of adipose tissue maturation disorder and dysfunction, in order to cope with the direct cause of T2DM.

CONCLUSION

Among variety of oral antihyperglycemic agents, during the tailoring of appropriate individual therapy for overweight and obese patients with T2DM, it is necessary to bear in mind their impact on the function of adipose tissue. Priority should be given to those groups of agents that stimulate the differentiation and maturation of preadipocytes, have a positive effect on the secretion of adipokines, and exert a protective effect on the redistribution of fat mass, through reduction of the amount of visceral adipose tissue depots and increase in the amount of subcutaneous adipose tissue departments.

REFERENCES

1. Popovic DS, Tomic-Naglic D, Stokic E. Relation of resistin, leptin, adiponectin-Trinity of adipose tissue dysfunction assessment. Eur J Intern Med. 2014; 25(6):80–1.
2. Tomic-Naglic D, Popovic DS, Mitrovic M, Novakovic-Paro J, Srdic-Galic B, Ruzic M, et al. Ferritin and cardiovascular risk in obese persons. Int J Med Biomed Sci. 2015; 3:12–7.
3. Tomić-Naglić D, Stokić E, Srdić B, Radovanov T. Masno tkivo kao endokrina žlezda. Medicina Danas. 2008; 7:141–7.
4. Stokić E, Kupusinac A, Tomic-Naglic D, Smiljenic D, Kovacev-Zavisic B, Srdic-Galic B, et al. Vitamin D and dysfunctional adipose tissue in obesity. Angiology. 2015; 66(7):613–8.
5. Stokić E, Kupusinac A, Tomić-Naglić D, Kovacev-Zavisic B, Mitrovic M, Smiljenic D, et al. Obesity and vitamin D deficiency: trends to promote a more proatherogenic cardiometabolic risk. Angiology. 2015; 66(3):237–43.
6. Popovic DS, Stokic E, Tomic-Naglic D, Novakovic-Paro J, Mitrovic M, Vukovic B, et al. Surrogates of insulin sensitivity and indices

7. of cardiometabolic profile in obesity. Curr Vasc Pharmacol. 2017; 15(4):380–9.
8. Popovic DS, Mitrovic M, Tomic-Naglic D, Icin T, Bajkin I, Vukovic B, et al. The Wnt/β-catenin signalling pathway inhibitor sclerostin is a biomarker for early atherosclerosis in obesity. Curr Neurovasc Res. 2017; 14(3):200–6.
8. Chae YN, Kim TH, Kim MK, Shin CY, Jung IH, Sohn YS, et al. Beneficial effects of evogliptin, a novel dipeptidyl peptidase 4 inhibitor, on adiposity with increased Ppargc1a in white adipose tissue in obese mice. PLoS One. 2015; 10(12):e0144064
9. Majdi MA, Mohammadzadeh NA, Lotfi H, Mahmoudi R, Alipour FG, Shool F, et al. Correlation of Resistin Serum Level with Fat Mass and Obesity-Associated Gene (FTO) rs9939609 Polymorphism in Obese Women with Type 2 Diabetes. Diabetes Metab Syndr. 2017; 11 Suppl 2:S715–20.
10. Marathe P, Gao HX, Close KL. American Diabetes Association standards of medical care in diabetes 2017. J Diabetes. 2017; 9(4):320–4.

11. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006; 368(9548):1673–9.

12. Inzucchi SE, Bergenstal MR, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient central approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38(1):140–9.

13. Cadegiani FA, Silva OS. Acarbose promotes remission of both early and late dumping syndromes in post-bariatric patients. Diabetes Metab Syndr Obes. 2016; 9:443–6.

14. Brunetti L, DeSantis EH. Patient tolerance and acceptance of colesevelam hydrochloride: focus on type 2 diabetes mellitus. Pharmacy and Therapeutics. 2015; 40(1):62–7.

15. Shivaprasad C, Kalra S. Bromocriptine in type 2 diabetes mellitus. Indian J Endocrinol Metab. 2011; 15:17–24.

16. Aronoff SL. Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes. Postgrad Med. 2017; 129(2):231–41.

17. Fujita K, Iwama H, Oura K, Tadokoro T, Hirose K, Watanabe M, et al. Metformin-suppressed differentiation of human visceral preadipocytes: involvement of microRNAs. Int J Mol Med. 2016; 38(4):1135–40.

18. Tan BK, Chen J, Farhatullah S, Adya R, Kaur J, Heutling D, et al. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes. 2009; 58(9):1971–7.

19. Lundkvist P, Sjostrom CD, Amini S, Pereira MJ, Johnsson E, Eriksson JW. Dapagliflozin once-daily and exenatide once-weekly dual therapy: a 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. Diabetes Obes Metab. 2017; 19(1):49–60.

20. Rohrborn D, Bruckner J, Sell H, Eckel J. Reduced DPP4 activity improves insulin signaling in primary human adipocytes. Biochem Biophys Res Commun. 2016; 471(3):348–54.

21. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008; 57(6):1723–9.

22. Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A, et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017; 16(1):8.

23. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22):2117–28.

24. Kusaka H, Koibuchi N, Hasagawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016; 15(1):157.

25. Ren R, Chen Z, Zhao X, Sun T, Zhang Y, Chen J, et al. A possible regulatory link between Twist 1 and PPRγ gene regulation in 3T3-L1 adipocytes. Lipids Health Dis. 2016; 15(1):189.

26. Srdić B, Stokić E, Korać A, Ukropina M, Veličković K, Breberina M. Morphological characteristics of abdominal adipose tissue in normal-weight and obese women of different metabolic profiles. Exp Clin Endocrinol Diabetes. 2010; 118(10):713–8.

27. Virtanen KA, Hallsten K, Parkkola R, Janatuinen T, Lonnqvist F, Viljanen T, et al. Differential effect of rosiglitasone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes. 2003; 52(2):283–9.

28. Hammarstedt A, Rotter Sopasakis V, Gogg S, Jansson PA, Smith U. Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin resistant subjects. Diabetologia. 2015; 48(1):96–104.

29. Stokić E, Tomić-Naglić D, Đerić M, Jorga J. Therapeutic options for treatment of cardiometabolic risk. Med Pregl. 2009; 62:54–8.

30. Chen J, Sang Z, Li L, He L, Ma L. Discovery of 5-methyl-2-(4-((4-(methylsulfonyl) benzyl)oxy)phenyl)-4-(piperazin-1-yl) pyrimidinederivatives as novel GRP119 agonists for the treatment of diabetes and obesity. Mol Divers. 2017; 21(3):637–54

31. Koska J, Lopez L, D'Souza K, Osredkar T, Deer J, Kurtz J, et al. The effect of liraglutide on dietary lipid induced insulin resistance in humans. Diabetes Obes Metab. 2017. [Epub ahead of print]

32. Pastel E, Joshi S, Knight B, Liversedge N, Ward R, Kos K. Effects of exendin-4 on human adipose tissue inflammation and ECM remodeling. Nutrition & Diabetes. 2016; 6(12):e235.

33. Sanlioglu AD, Altunbas HA, Balci MK, Griffith TS, Sanlioglu S. Clinical utility of insulin and insulin analogs. Islets. 2013; 5(2):67–78.

Утицај савремених оралних антихипергликемијских лекова на дисфункционално масно ткиво

Драгана Томић-Наглић[1,2], Милена Митровић[1,2], Јованка Новаковић-Паро[1,2], Радослав Пејин[1,2], Ђорђе С. Поповић[1,2], Слађана Пејаковић[1], Биљана Срдић-Галић[2], Дамир Бенц[1,2]

[1]Клинички Центар Војводине, Клиника за ендокринологију, дијабетес и болести метаболизма, Нови Сад, Србија;
[2]Универзитет у Новом Саду, Медицински факултет, Нови Сад, Србија

САЖЕТАК
Гојазност је болест са пандемијском учесталошћу, коју прате хроничне метаболичке и органске компликације. Међу најчешће метаболичке компликације гојазности спада тип 2 шећерне болести, а први корак у њеном лечењу је нутритивна терапија уз дозирану физичку активност и редукцију телесне масе. Медикаментно лечење се започиње метформином, а у случају неадекватног успеха додају се и други антихипергликемијски лекови. Са дериватима сулфонилуреје постоји највеће клиничко искуство, али је њихова употреба ограничена јер изазивају учестале хипогликемије и пораст телесне масе. У светлу сазнања да је масно ткиво ендокрини орган и да управо дисфункција овог ткива доводи до хроничних компликација, императив у савременој терапији је употреба лекова са снажним ефектом на функционалност овог ткива. Антихипергликемијски лекови избора код гојазних особа су они који доводе до матурације адипоцита, лучења протективних адипоцитокина и редистрибуције масне масе из висцералних у субкутане депое. Орални хипогликемијски агенси који утичу на функционалност масног ткива су метформин, СГЛТ-2 инхибитори, ДПП-4 инхибитори и тиазолидиндиони.
Кључне речи: масно ткиво; адипоцитокини; тип 2 дијабетеса; терапија